The only story here that matters is CurifyLabs—and not for the hype. Personalized 3D-printed medicine hitting the US market signals the first real vertical where on-demand manufacturing actually solves a problem you can't solve any other way (dosing, geometry, drug combinations tailored to individual patients). That's different from the endless "we 3D-printed a thing" noise. The firmware drops (Marlin, Prusa) are table stakes—ignore unless you're actively debugging. SUNLU filament at $38-$41/4kg is just commodity pricing doing its job; watch it only if you're buying in volume and need to track cost trends. The laser-stirring alloy work is genuinely interesting R&D but completely decoupled from what's actually printing yet—flag it for 2027, not now.